Compare CTO & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTO | CTMX |
|---|---|---|
| Founded | 1902 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 772.2M | 716.9M |
| IPO Year | 1995 | 2015 |
| Metric | CTO | CTMX |
|---|---|---|
| Price | $19.67 | $2.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $24.60 | $12.25 |
| AVG Volume (30 Days) | 291.1K | ★ 2.8M |
| Earning Date | 10-27-2026 | 11-09-2026 |
| Dividend Yield | ★ 7.68% | N/A |
| EPS Growth | ★ 122.86 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $149,545,000.00 | $76,201,000.00 |
| Revenue This Year | $18.22 | N/A |
| Revenue Next Year | $12.10 | $1.24 |
| P/E Ratio | $152.27 | ★ $22.58 |
| Revenue Growth | ★ 20.10 | N/A |
| 52 Week Low | $16.17 | $2.20 |
| 52 Week High | $22.71 | $8.21 |
| Indicator | CTO | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 36.02 |
| Support Level | $19.49 | $2.20 |
| Resistance Level | $20.08 | $3.93 |
| Average True Range (ATR) | 0.46 | 0.15 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 8.51 | 8.94 |
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.